Glukóza Viaflo Baxter

Glukóza Viaflo Baxter is an intravenous solution for injection that contains glucose monohydrate as the active ingredient. The product’s strength is not specified in the available data, and it is supplied as a solution intended for administration. It is marketed in the European Union and is classified under ATC code B05BA02. It belongs to the drug class of intravenous carbohydrate solutions used to restore blood glucose levels and support fluid balance.

Glukóza Viaflo Baxter is indicated for several clinical situations where rapid glucose supplementation or fluid balance is required.

- Treatment of acute hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens to provide carbohydrate calories. - Support of fluid and electrolyte replacement during surgery or critical illness. - Management of glucose deficits in patients receiving prolonged fasting. - Adjunctive therapy for patients with insulin‑dependent diabetes experiencing severe low blood sugar.

Intravenous administration of glucose solutions can be associated with both common and less frequent adverse reactions.

Common: - Mild hyperglycemia. - Local irritation at the injection site. - Nausea or vomiting. - Headache. - Transient electrolyte shifts (e.g., low potassium). - Transient increase in serum osmolality.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic or anaphylactic reaction to the formulation. - Hyperosmolar hyperglycemic state. - Fluid overload causing pulmonary edema. - Metabolic acidosis in susceptible patients. - Seizures related to severe electrolyte imbalance.

Before using Glukóza Viaflo Baxter, clinicians should consider several precautionary measures to ensure safe administration.

- Verify blood glucose level and avoid administration if hyperglycemia is present. - Adjust dose in patients with renal or hepatic impairment. - Monitor electrolyte concentrations, especially potassium and sodium, during therapy. - Use caution in patients with heart failure or at risk of fluid overload. - Assess for history of hypersensitivity to glucose solutions or excipients. - Avoid rapid infusion rates unless clinically indicated. - Ensure aseptic technique to prevent catheter‑related infections.

Glucose infusion may interact with other medications or clinical conditions, requiring attention to avoid adverse outcomes.

Avoid: - Co‑administration with insulin without appropriate glucose monitoring. - Concurrent use of high‑dose diuretics that may exacerbate electrolyte disturbances. - Administration with hypertonic saline solutions that could increase osmolar load.

Use with caution: - Beta‑blockers, which may mask signs of hypoglycemia. - Corticosteroids, which can raise blood glucose levels. - Catecholamines (e.g., epinephrine) that may affect glucose metabolism. - Sodium‑glucose cotransporter‑2 (SGLT2) inhibitors, requiring close monitoring. - Total parenteral nutrition mixtures, to prevent excessive carbohydrate load.